arrow
N

Nozomu Machida

Kanagawa Cancer Center
H指数:27
被引数:2,741

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Role of tumor markers before or during chemotherapy for digestive neuroendocrine carcinomas as an exploratory analysis of JCOG1213

消化神经内分泌癌化疗前或化疗期间肿瘤标志物的角色:JCOG1213的探索性分析

2026-04-160
OAAI
Nivolumab in combination with radiotherapy for unresectable advanced or recurrent gastric cancer (CIRCUIT trial): A 5-year update of the progression-free survival and local control outcomes

纳武利尤单抗联合放疗治疗不可切除的局部晚期或复发性胃癌(CIRCUIT试验):无进展生存期和局部控制结局的5年更新

2026-03-190
OAAI
An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study

一项关于纳武利尤单抗联合化疗在未经治疗的晚期或复发性胃癌日本真实世界中的有效性与安全性观察研究:G-KNIGHT研究

2025-07-090
OAAI
Efficacy of nodal dissection for locoregional gastric neuroendocrine carcinoma: a multicenter retrospective observational study

淋巴结清扫术对局部区域胃神经内分泌癌的疗效:一项多中心回顾性观察性研究

2025-06-300
PRE
The efficacy and safety of FOLFOX therapy for advanced esophageal squamous cell carcinoma

FOLFOX治疗晚期食管鳞癌的疗效和安全性

2025-03-070
OAAI
Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301C (Trigger Study)

S-1/CDDP术前化疗加或不加曲妥珠单抗,然后手术治疗HER2-positive可切除的胃或食管胃结合部腺癌伴广泛淋巴结转移的随机II期临床试验的早期终点: 日本临床肿瘤学组研究JCOG1301C (触发研究)

2024-01-192
PRE
Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer
2023-08-151
OA
Clinical Effect of the C-Reactive Protein to Serum Albumin Ratio in Patients with Metastatic Gastric or Gastroesophageal Junction Cancer Treated with Trifluridine/Tipiracil
2023-05-312
OA